All In Biotech

Drug Trial Radar · NCT04203342

A Therapeutic Equivalence Study of Ketoconazole Cream 2%

A Randomized,Double-blind,Vehicle-controlled, Parallel-design,Multiple-site Study to Evaluate the Therapeutic Equivalence of Ketoconazole Cream 2% (Douglas Pharmaceuticals America Ltd) to Ketoconazole Cream 2% (Teva Pharmaceuticals USA Inc.) in the Treatment of Tinea Pedis.

Last checked: Nov 20, 2026Latest source record: Aug 6, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 682 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

682

Actual

Start

Dec 11, 2019

Primary completion

May 28, 2020

Study completion Jul 13, 2020

Sponsor

Sponsor type
Industry
Collaborators
Novum Pharmaceutical Research Services; ACM Global Laboratories
First posted
Dec 18, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Clinical Study to Evaluate the Therapeutic Equivalence of Ketoconazole Cream 2% in the Treatment of Tinea Pedis.

Conditions

  • Tinea Pedis

Interventions

  • Experimental: Ketoconazole 2% Cream (Douglas Pharmaceuticals America Ltd.)Drug

    Topical treatment for tinea pedis. Subjects will be instructed to apply sufficient study product to cover affected and immediate surrounding areas once daily for 42 +/- 4 days. Each subject is expected to receive 42 +/- 4 doses.

  • Active comparator: Ketoconazole 2% Cream (Teva Pharmaceuticals USA)Drug

    Topical treatment for tinea pedis. Subjects will be instructed to apply sufficient study product to cover affected and immediate surrounding areas once daily for 42 +/- 4 days. Each subject is expected to receive 42 +/- 4 doses.

  • Placebo comparator: Placebo (Douglas Pharmaceuticals America Ltd.)Drug

    Topical placebo to treatment for tinea pedis. Subjects will be instructed to apply sufficient study product to cover affected and immediate surrounding areas once daily for 42 +/- 4 days. Each subject is expected to receive 42 +/- 4 doses.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Therapeutic cure of tinea pedisTime frame: 2 weeks post-treatment (Day 56)

Locations

3 sites in 2 countries. Site status is shown where the registry gives one.

  • Moore Clinical Research

    Brandon, Florida

  • Moore Clinical Reseach

    Tampa, Florida

  • FXM Research International

    Belize City, Belize

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.